

Mangalam Drugs and Organics Limited



Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.

☎ 91-22-62616200 / 6300 / 8787 ☎ 91-22-62619090 • CIN : L24230MH1972PLC116413

REF: MDOL/CS-SE/2024-25/0028

October 14, 2024

To,
Listing Department
BSE Ltd
1st Floor, New Trade Wing,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001

Listing Department
National Stock Exchange of India
Limited
"Exchange Plaza", 5th Floor,
Plot No. C-1, Block G,
Bandra - Kurla Complex,
Bandra(E), Mumbai - 400 051

Scrip Code: 532637

Symbol: MANGALAM

Sub: Regulation 76 of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 - Reconciliation of Share Capital Audit Report for the quarter ended September 30, 2024

Dear Sir/Madam,

Pursuant to Regulation 76 of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, please find enclosed the Reconciliation of Share Capital Audit Report for the quarter ended September 30, 2024.

We request your good office to kindly take the above certificate on record and acknowledge receipt of the same.

Thanking you,

Yours faithfully,
For Mangalam Drugs & Organics Limited

Govardhan M. Dhoot
Managing Director
DIN:01240086



Mustafa Bohra & Associates Practising Company Secretaries

Address: Office No. B- 08 & 10, Wadala Udyog Bhawan, MMGS Marg,
Dadar (E), Wadala, Mumbai – 400031, Maharashtra, India.

Contact: +91 79996-65955 / +91 76930-19852 | **Email ID:** mustafa@asdt.in

RECONCILIATION OF SHARE CAPITAL AUDIT REPORT FOR QUARTER ENDED SEPTEMBER 2024

UNDER REGULATION 76 OF SEBI (DEPOSITORIES AND PARTICIPANTS) REGULATIONS, 2018

To,
MANGALAM Drugs & Organics Limited (*Hereinafter referred to as Company*)

CIN: L24230MH1972PLC116413

Address: 3rd Floor, RUPAM Building, 239, P.D' Mello Road,
Near G.P.O., Mumbai – 400001, Maharashtra, India.

Dear Sirs / Madam,

We have examined the relevant books, registers, forms, documents and papers produced before us by MANGALAM Drugs & Organics Limited and LINK INTIME India Private Limited, Registrars and Transfer Agent of the Company in respect of Reconciliation of Share Capital Audit as per the Regulation 76 of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018. To the best of our knowledge and according to the information and explanations given to us and as shown by the electronic records examined by us, we certify the following:

1.	For Quarter Ended	:	September, 2024
2.	ISIN	:	INE584F01014
3.	Face Value	:	Rs. 10/- each
4.	Name of the Company	:	Mangalam Drugs and Organics Limited
5.	Registered Office Address	:	3 rd Floor, Rupam Building 239, P. D' Mello Road Mumbai -400001, Maharashtra, India
6.	Correspondence Address	:	3 rd Floor, Rupam Building 239, P. D' Mello Road Mumbai -400001, Maharashtra, India

7.	Telephone & Fax No.	:	Tel. 022-22616200 / 6300 / 8787 Fax 022- 22619090	
8.	Email Address	:	contactus@mangalamdrugs.com	
9.	Website	:	https://www.mangalamdrugs.com/	
10.	Name of the stock exchange where Company's Securities are Listed	:	BSE and NSE	
			No. of shares	% Of Total Issued capital
11.	Issued Capital	:	1,58,28,248	100 %
12.	Listed Capital	:	1,58,28,248	100 %
13.	Held in dematerialized form in CDSL	:	59,25,104	37.43 %
14.	Held in dematerialized form in NSDL	:	99,03,134	62.57 %
15.	Physical	:	10	0.00 %
16.	Total No. of Shares (13+14+15)	:	1,58,28,248	100 %
17.	Reason for difference if any, between (11 & 12), (11 & 16), (12 & 16)	:	NA	NA
18.	Certifying the details of Changes in Share Capital during quarter under consideration as per Table below: Nil			

Particulars*	No of Shares	Applied / Not applied For listing	Listed on Stock Exchange (specify Name) for listing	Whether intimated to CDSL	Whether intimated to NSDL	In- Principal approval pending for Stock Exchange (specify names)
No Change						

* Rights, Bonus, Preferential Issue, ESOP's, Amalgamation, Conversion, buy back, Capital Reduction, Forfeiture, any other (to specify).

19.	Register of Members is updated (Yes / No)	:	Yes
20.	Reference to previous quarter with regards to excess dematerialization of shares, if any	:	Not Applicable
21.	Has the company resolved the matter mentioned in Point No. 20 above in the Current Quarter	:	Not Applicable

22.	Mention the total no. of Request, if any, confirmed after 21 days and the total no. of requests pending beyond 21 days with the reasons for delay	:	Total No. of Demat Requests	No. of Requests	No. of Shares	Reasons for Delay
			Confirmed after 21 days	Nil	Nil	Nil
Pending for more than 21 Days	Nil	Nil	Nil			
23.	Name, Telephone & Fax No. of the Compliance officer of the Company as on September 30, 2024.	:	Ms. Anuradha Pandey Membership No: A72902 Tel No : 022-22616200 / 6300 / 8787 Fax No : 022-22619090			
24.	Name, Address, Telephone, Registration No. of the Auditor	:	M/s. Mustafa Bohra & Associates Mr. Mustafa Bohra Practising Company Secretaries Address: Office No. B- 08 & 10, Wadala Udyog Bhawan, MMGS Marg, Dadar (E), Wadala, Mumbai – 400031, Maharashtra, India Contact No : +91 79996-65955 Email ID : mustafa@asdt.in M. No. : A61727 COP No : 24345 FRN : S2021MP794700 Peer Review Certificate No: 5680			
25.	Appointment of common agency for share registry work if yes (Name & Address)	:	LINK INTIME India Private Limited, Address: C - 101, 247 Park, L.B.S. Marg, Vikhroli (West), Mumbai – 400083, Maharashtra, India. Tel No : +91 22 4918 6000 Email ID : mumbai@linkintime.co.in / rnt.helpdesk@linkintime.co.in			
26.	Any other details that the Auditor may like to provide (E.g., BIFR Company, delisting from SE, Company changed its Name, etc.)	:	Nil			

Place : Mumbai
Date : 09.10.2024

M/s. Mustafa Bohra & Associates
Practising Company Secretaries



Mr. Mustafa Bohra
Proprietor

ACS : 61727

C.P No : 24345

FRN : S2021MP794700

PR No : 5680

UDIN : A061727F001506940